SFS
SRPT icon

Signator Financial Services’s Sarepta Therapeutics SRPT Stock Holding History

Signator Financial Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$8K Hold
166
– – 0.01% 217
2013
Q2 		$6K Buy
+166
New +$5.94K 0.01% 230

Other funds holding SRPT

Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Signator Financial Services's SRPT Position: Q3 2013 in Review

Signator Financial Services held its Sarepta Therapeutics (SRPT) position steady in Q3 2013 at 166 shares worth $8K. The position accounts for 0.01% of the portfolio, ranked #217.

Signator Financial Services first reported a position in SRPT in Q2 2013 and has held it in 2 quarters since. 134 funds tracked by Wall St. Rank hold SRPT as of Q3 2013.

  • Signator Financial Services held 166 shares of Sarepta Therapeutics worth $8K as of Q3 2013.
  • Signator Financial Services left its Sarepta Therapeutics share count unchanged in Q3 2013.
  • Sarepta Therapeutics made up 0.01% of Signator Financial Services's portfolio in Q3 2013, its #217 holding.
  • Signator Financial Services first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 2 quarters since.
  • 134 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2013.

Based on Signator Financial Services's 13F filing for Q3 2013, filed 25 Aug 2014.